Ocular surface complications of local anticancer drugs for treatment of ocular tumors

Moon, Jin Young; Choi, Se Hyun; Lee, Min Joung; Jo, Dong Hyun; Park, Un Chul; Yoon, Sun Woo; Woo, Se Joon; Oh, Joo Youn

doi:10.1016/j.jtos.2020.11.006

Cited by 6 publications

(5 citation statements)

References 198 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Supporting this idea, no patients discontinued the use of the drug; An average of 4.22 cycles of treatment were needed to observe resolution of the lesions, which translates to approximately 59 days in these cycles and 29.5 days of actual administration of the drug, which is similar to the period of time in other studies were treatment was applied continuously. The similitude in the number of days of application could be explained by the fact that cell toxicity is dose dependent [ 33 , 34 ]. With this in mind, 100% of the patients included in this study presented a complete resolution of the injury.…”

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy

Alvarado-Castillo,

Santa Cruz-Pavlovich,

Gonzalez-Castillo

et al. 2023

BMC Ophthalmol

View full text Add to dashboard Cite

Purpose Ocular surface squamous neoplasia (OSSN) comprises a wide spectrum of squamous tumors, from which corneal/conjunctival intraepithelial neoplasia (CIN) is the most common one. The classic treatment is complete excision, but recurrence rates are high. Antineoplastic drugs such as mitomycin C (MMC) and interferon alpha 2b (IFNα2b) have been used as adjuvants or as primary treatment. To evaluate the efficacy and safety of topical IFNα2b and MMC in patients with CIN, a phase IIb double-blind clinical trial was performed. Methods Patients diagnosed with localized CIN were evaluated by slit lamp and impression cytology and were randomly given MMC 0.04% or INF2b (1 million IU/mL) 4 times daily until neoplasia resolution. Time of resolution and frequency of adverse effects were analyzed to determine the pharmacological efficacy and safety of both medications. Results Seventeen patients were included. Nine patients were treated with MMC and 8 with IFNα2b. All patients responded to treatment. The resolution time in days was 59.11 ± 24.02 in patients treated with MMC and 143.50 ± 47.181 in those treated with IFNα2b (p < 0.001). In the MMC group, one recurrence was reported (11%). There were no recurrences at 2 years of follow-up in the IFNα2b group. Regarding adverse effects, one or more mild adverse reaction occurred in 77% of patients managed with MMC and in 50% of patients managed with IFNα2b (p > 0.05). No serious adverse effects were reported. Conclusions Topical chemotherapy with MMC and IFNα2b demonstrate pharmacological safety and efficacy. Therefore, these drugs could be considered as primary therapies for localized CIN .

show abstract

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy

Alvarado-Castillo,

Santa Cruz-Pavlovich,

Gonzalez-Castillo

et al. 2023

BMC Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Therefore, loss of pRb leads to unregulated cell cycle progression, reduced apoptosis and uncontrolled cell proliferation (2,3). Several chemotherapies, radiotherapies and thermotherapies have been used to treat retinoblastoma (4)(5)(6). However, numerous patients experience recurrence or symptoms related to the toxicity of chemotherapies, and enucleation is still often implemented, which significantly affects the quality of life after operation (4).…”

Section: Introductionmentioning

confidence: 99%

Inhibition of protein arginine deiminase II suppresses retinoblastoma in orthotopic transplantation in mice

et al. 2023

View full text Add to dashboard Cite

Chemotherapies are used for treating retinoblastoma; however, numerous patients suffer from recurrence or symptoms due to chemotherapy, which emphasizes the need for alternative therapeutic strategies. The present study demonstrated that protein arginine deiminase II (PADI2) was highly expressed in human and mouse retinoblastoma tissues due to the overexpression of E2 factor (E2F). By inhibiting PADI2 activity, the expression of phosphorylated AKT was reduced, and cleaved poly (ADP-ribose) polymerase level was increased, leading to induced apoptosis. Similar results were obtained in orthotopic mouse models with reduced tumor volumes. In addition, BB-Cl-amidine showed low toxicity in vivo. These results suggested that PADI2 inhibition has potential clinical translation. Furthermore, the present study highlights the potential of epigenetic approaches to target RB1-deficient mutations at the molecular level. The current findings provide new insights into the importance of retinoblastoma intervention by managing PADI2 activity according to the treatment of specific inhibitors and depletion approaches in vitro and in orthotopic mouse models.

show abstract

“…This approach has been found to be effective in reducing systemic side effects such as ischemic necrosis, orbital fat necrosis, atrophy of the optic nerve, and disturbances of ocular motility. 4,15,[20][21][22] Compared to internal organs, the eye is an easily accessible tissue for local delivery, making the locoregional (eye drops and local injections) administration of chemotherapeutics an attractive choice for the management of retinoblastoma. Considering that anticancer drugs can be directly administered into the eye (local injections), the blood-ocular barrier can be circumvented, thereby maximizing drug concentration, and minimizing its systemic absorption.…”

Section: Introductionmentioning

confidence: 99%

“…Considering that anticancer drugs can be directly administered into the eye (local injections), the blood-ocular barrier can be circumvented, thereby maximizing drug concentration, and minimizing its systemic absorption. 21 Intravitreal drug delivery has become the gold standard for the treatment of many retinal diseases and is considered an efficient approach to delivering chemotherapy and other drugs to the retina at therapeutic levels. [23][24][25] However, this approach can be hampered by the lack of patient adherence, injection site discomfort, subconjunctival hemorrhage, and possibility of retinal detachment, among others.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Advances in biomaterials for the treatment of retinoblastoma

et al. 2022

View full text Add to dashboard Cite

show abstract

Ocular surface complications of local anticancer drugs for treatment of ocular tumors

Cited by 6 publications

References 198 publications

Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy

Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy

Inhibition of protein arginine deiminase II suppresses retinoblastoma in orthotopic transplantation in mice

Advances in biomaterials for the treatment of retinoblastoma

Contact Info

Product

Resources

About